

Medical information

Issues in the management of relapsed and refractory diffuse large B-cell lymphoma in 2022 with focus on new therapies

Incyte Nordics has the pleasure to invite you to a virtual meeting where Georg Hess, MD and professor at the hematology department at the Johannes Gutenberg University in Mainz, Germany will present the latest scientific data in the treatment of patients with R/R DLBCL.



Wednesday 23rd
of March, 2022



15.00 – 16.30 CET

Agenda

Introduction by Incyte

What available therapies do we have to treat patients with R/R DLBCL?

- What is the goal with the therapy?
- How do we select right treatment for our patients?
- What is a reasonable treatment sequence?

Learnings and experience of tafasitamab use in combination with lenalidomide

- L-MIND data
- Clinical experience
- Patient cases

Q&A

Sign up to the virtual meeting by sending an e-mail to dthunstrom@incyte.com

